Evaluating the Effect of Non-cellular Bioactive Glass-Containing Scaffolds on Osteogenesis and Angiogenesis in in vivo Animal Bone Defect Models by Ranmuthu, Chanuka D. S. et al.
SYSTEMATIC REVIEW
published: 14 May 2020
doi: 10.3389/fbioe.2020.00430
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 1 May 2020 | Volume 8 | Article 430
Edited by:
Francesco Baino,
Politecnico di Torino, Italy
Reviewed by:
Anuj Kumar,
Yeungnam University, South Korea
Saeid Kargozar,
Mashhad University of Medical
Sciences, Iran
Emanuel Ionescu,
Darmstadt University of
Technology, Germany
*Correspondence:
Wasim S. Khan
wk280@cam.ac.uk
Specialty section:
This article was submitted to
Biomaterials,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 09 December 2019
Accepted: 15 April 2020
Published: 14 May 2020
Citation:
Ranmuthu CDS, Ranmuthu CKI,
Russell JC, Singhania D and Khan WS
(2020) Evaluating the Effect of
Non-cellular Bioactive
Glass-Containing Scaffolds on
Osteogenesis and Angiogenesis in in
vivo Animal Bone Defect Models.
Front. Bioeng. Biotechnol. 8:430.
doi: 10.3389/fbioe.2020.00430
Evaluating the Effect of Non-cellular
Bioactive Glass-Containing Scaffolds
on Osteogenesis and Angiogenesis
in in vivo Animal Bone Defect Models
Chanuka D. S. Ranmuthu 1, Charindu K. I. Ranmuthu 1, Jodie C. Russell 1, Disha Singhania 1
and Wasim S. Khan 2*
1Cambridge Clinical School, University of Cambridge, Cambridge, United Kingdom, 2Division of Trauma and Orthopaedics,
Department of Surgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
The use of bone scaffolds to replace injured or diseased bone has many advantages over
the currently used autologous and allogeneic options in clinical practice. This systematic
review evaluates the current evidence for non-cellular scaffolds containing bioactive glass
on osteogenesis and angiogenesis in animal bone defect models. Studies that reported
results of osteogenesis via micro-CT and results of angiogenesis via Microfil perfusion
or immunohistochemistry were included in the review. A literature search of PubMed,
EMBASE and Scopus was carried out in November 2019 fromwhich nine studiesmet the
inclusion and exclusion criteria. Despite the significant heterogeneity in the composition
of the scaffolds used in each study, it could be concluded that scaffolds containing
bioactive glass improve bone regeneration in these models, both by osteogenic and
angiogenic measures. Incorporation of additional elements into the glass network, using
additives, and using biochemical factors generally had a beneficial effect. Comparing
the different compositions of non-cellular bioactive glass containing scaffolds is however
difficult due to the heterogeneity in bioactive glass compositions, fabrication methods
and biochemical additives used.
Keywords: scaffolds, bone, bioactive glass, osteogenesis, angiogenesis
INTRODUCTION
Bones are composed of a dense connective tissue and they serve a large variety of functions.
These include mechanical functions such as internal organ protection, synthetic functions such
as hematopoiesis within the bone marrow and metabolic functions such as acting as reservoirs
for minerals (Taichman, 2005). Thus, the repair of bone defects caused by trauma, infection
and congenital abnormalities is important (Zhao et al., 2015). Many methods to achieve
regeneration have been investigated, including the “gold standard” autologous bone grafting,
allograft implantation, or autologous bone transplantation. However, these methods are not
without their limitations, especially with regards to cost-effectiveness and even efficacy (Dimitriou
et al., 2011). One of the alternative methods proposed is to focus on regenerating the tissue through
tissue engineering, rather than replacing it (Langer, 2000). Commonly in tissue engineering,
templates or “scaffolds” are used to provide an appropriate environment for this tissue regeneration
(O’Brien, 2011). Scaffolds can be seeded with cells and growth factors in order to aid this process.
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The ideal properties of a scaffold have been described
previously (O’Brien, 2011). Firstly, the scaffold must be
biocompatible, allowing for cells to migrate through the scaffold
and lay down new matrix. They must elicit a negligible immune
reaction to prevent any inflammatory process from reducing
healing of the bone. They should also be biodegradable, with
degradation products being non-toxic. Having both mechanical
properties and sufficient porosity to function adequately from
the implantation to remodeling stage is also important. An
interconnected pore structure within the scaffold is crucial to
facilitate the penetration of cells and diffusion of nutrients.
Research suggests that the minimum pore size for bone
regeneration is 100µm (Wagoner Johnson and Herschler, 2011).
Other properties described (Wagoner Johnson and Herschler,
2011) include the ability to serve as a template for bone formation
by allowing cells to adhere and proliferate (osteoconductivity).
They should also be able to bind with surrounding bone
tissue (bioactivity) and ideally have the ability to induce bone
formation (osteoinductivity). Furthermore, a strong correlation
between decreased vascular function and failed bone healing
has been described in the literature previously (Dickson et al.,
1994). The importance of re-establishing an adequate blood
vessel system has been comprehensively reviewed previously
(Stegen et al., 2015). Indeed, the low survival of osteogenic
cells after implantation of the scaffold in the early stages of
bone regeneration has been attributed to an inadequate rate
of blood vessel invasion into the scaffold (Giannoni et al.,
2010; Stegen et al., 2015). Thus, scaffolds that have potential to
provide better angiogenesis are also sought after (Rouwkema and
Khademhosseini, 2016).
A plethora of scaffolds made from different biomaterial
groups have been investigated in the field, including but
not limited to calcium phosphate bioactive ceramic scaffolds,
polymeric scaffolds, composite scaffolds, and metallic scaffolds
(Bose et al., 2012). Bioactive glass scaffolds have also recently
gained attention. The first bioactive glass introduced was
Abbreviations: 45S5, glass with 45 wt.% of SiO2 and 5:1 molar ratio of calcium to
phosphorous; α-SMA, alpha-smooth muscle actin; BMD, bone mineral density;
BMP-2, human bone morphogenetic protein-2; BV/TV, bone volume/total bone
volume i.e., bone volume fraction; CD31, cluster of differentiation 31; CD34,
cluster of differentiation 34; Cu-BG/CH/SF/GP, copper-doped bioactive glass with
chitosan/silk fibroin/glycerophosphate concentration 1; Cu-BG/CH/SF/GP(II),
copper-doped bioactive glass with chitosan/silk fibroin/glycerophosphate
concentration 2; DMOG, dimethyloxallyl glycine; ECM, extracellular matrix;
FTY720, fingolimod; GelMA, gelatin methacryloyl; GelMa-G-MBGNs, MGBN
with photo-cross-linkable GelMAwhich have been further integrated into GelMA;
HCA, hydroxycarbonated apatite; HIF-1, hypoxia-inducible factor-1; HIF-PH,
hypoxia-inducible factor prolyl hydroxylase; IGF-II, insulin-like growth factor II;
M, months; MBG, mesoporous bioactive glass; MBGN, mesoporous bioactive glass
nanoparticle; MBG-LGO, MBG-low graphene oxide; MBG-HGO, MBG-high
graphene oxide; MBG-PHBHHx, MBG-doped poly(3-hydroxybutyrate-co-3-
hydroxyhexanoate); Mm, millimeters; MMP-2, matrix metallopeptidase-2; MPHS,
MBG with poly(3-hydroxybutyrate-co-3-hydroxyhexanoate); PHMB, BMP-2
+ MBG-PHBHHx; PHMBD, BMP-2 + DMOG + MBG-PHBHHx; PHMD,
DMOG + MBG-PHBHHx; PHMG, pure MBG-PHBHHx; PLGA, poly(lactic-
co-glycolic acid); RANKL, receptor activator of nuclear factor kappa-B ligand;
rhBMP-2, recombinant human bone morphogenetic protein-2; TEOS, tetraethyl
orthosilicate; TEP, triethyl phosphate; VEGF, vascular endothelial growth factor;
W, weeks; Wt, weight.
the 45S5 Bioglass R© introduced by Hench et al. (1971) and
was composed of a quaternary SiO2-CaO–Na2O–P2O5 oxide
system. It was “bioactive” in the sense that it could form a
hydroxycarbonated apatite (HCA) layer on the glass surface
upon contacting solutions mimicking human plasma, allowing
for a bonding interface with the bone tissue (Hench, 1991).
Many other bioactive glasses have similar oxide compositions
to the original 45S5 Bioglass R©, but with varying concentrations
(Brauer, 2015)—some such compositions reviewed in this article
are displayed in Table 1. One of the key features of bioactive
glasses are that they release ionic dissolution products which
can control osteoblastic gene expression, allowing for their bone
regenerative ability (Xynos et al., 2001). Further, bioactive glass
is able to release soluble ions (such as Si, Ca, P, Na ions) at
the rate required for proliferation and differentiation of cells
(Larry and Hench, 2006; El-Rashidy et al., 2017). Previous
investigations have established that they are osteoconductive
and osteoinductive too (Hench et al., 2014). Recently, bioactive
glass has gained traction because of its ability to induce the
angiogenesis needed for bone regeneration, as aforementioned
(Kargozar et al., 2018a). This could provide a more cost-effective
way of promoting neovascularization than the use of growth
factors (Rahaman et al., 2011). For example, some bioactive
glasses such as S53P4 (53% SiO2, 23%Na2O, 20%CaO, 4% P2O5)
have been shown to increase vascular endothelial growth factor
(VEGF) secretion to stimulate angiogenesis in bone (Detsch et al.,
2014). Authors have highlighted that investigating ways of the
promoting of angiogenesis as one of the most important topics in
regenerative medicine (Rouwkema and Khademhosseini, 2016).
Thus bioactive glasses may provide one such solution (Kargozar
et al., 2018a).
There has been a recent trend in adding other components
to the bioactive glass in order to aid regeneration. It has
been suggested that adding suitable dopants could influence
osteoblastic differentiation (Nohra et al., 2014). These include
metallic elements such as copper, strontium and borosilicate,
biochemical factors such as dimethyloxallyl glycine (DMOG) and
organic polymers such as photo-cross linkable gelatin derivative
containing gelatin and methacrylicanhydride (GeIMA). Khan
et al. found that adding strontium promoted early stage in vivo
osteointegration and bone remodeling (Khan et al., 2016). A
previous study, for example, showed that DMOG, an inhibitor
of the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-
PH), could mimic a hypoxic microenvironment and thereby
increase angiogenic capacity and osteogenic differentiation of
human bone marrow stromal cells (Wu et al., 2013a). Other
studies have indicated that bioactive glass andGeIMA composites
could encourage cell attachment and proliferation as well as
osteogenic differentiation.
There is a large body of evidence supporting the efficacy of
various types of bioactive glass scaffolds to induce angiogenesis
and osteogenesis in vitro. For example, Zhang et al. recently
found that their bioactive glass functionalized chondroitin sulfate
hydrogel had promoted the formation of a vascular network
(Zhang et al., 2019). Jia et al. looked at bioactive silicate (13–
93) and borosilicate (2B6Sr) glass scaffolds and found that they
were able to facilitate cell attachment and promoted formation of
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TABLE 1 | Study characteristics.
Paper Glass composition Glass fabrication method Scaffold fabrication method Animal Animal bone
defect
Added
components to
scaffold
Number of
defects
Groups
Jing et al.
(2018)
Bioactive glass: 45% SiO2,
24.5% Na2O, 24.5% CaO
and 6% P2O5 by percentage
weight
Not specified. The bioactive
glass was sourced from a
commercial source (Hubei
Central China Medical
Materials Co Ltd.)
45S5 Bioglass-based scaffolds
fabricated by the foam replication
method. The porous scaffolds were
loaded with Icariin, sterilized with
ultraviolet light and dried in a sterile
environment before cell seeding
Rat Skull None 1 circular
calvarial defect
with a diameter
of 8mm in 20
rats
1. Negative Control
2. 45S5 bioactive glass
3. 45S5 bioactive glass/autologous
stem cells (not relevant for this
study)
4. 45S5 bioactive glass/autologous
stem cells (not included in this
study)
5. Icariin/45S5 bioactive glass
scaffold/autologous stem cells (not
relevant for this study)
Wang et al.
(2019)
MBG: 80% Si, 15% Ca,
5% P by percentage mol
MBG: P123 (4.0 g), TEOS
(6.7 g),
Ca(NO3)2•4H2O (1.4 g), TEP
(0.36 g) with molar ratio of
Si:Ca:P = 80:15:5
MBG-GO scaffolds were calcined at
500◦C under nitrogen protection for
5 h
The scaffolds were sterilized using
gamma irradiation
Rat Skull None 2 critical-sized
calvarial defects
with a diameter
of 5mm in 24
rats
1. MBG scaffold
2. MBG-LGO scaffold (low
graphene oxide)
3. MBG-HGO scaffold (high
graphene oxide)
Wu et al.
(2019)
Bioactive glass: 95% SiO2,
2.5% CaO, 2.5% CuO by
percentage
mol
Cu-BG NPs with designed
compositions and sizes were
synthesized via a modified
Stöber method
Cu-BG NPs were incorporated into
chitosan (CH)/silk fibroin
(SF)/glycerophosphate (GP)
composites
Rat Skull Chitosan/silk
fibroin composite
2 full-thickness
calvarial bone
defects with
diameters of
5mm in 30 rats
1. Chitosan-silk fibroin-
glycerophosphate
2. Bioactive glass- Chitosan-silk
fibroin- glycerophosphate
3. Copper/Bioactive
glass-Chitosan+ silk
fibroin-glycerophosphate (1st
concentration)
4. Copper/Bioactive
glass-Chitosan+ silk
fibroin-glycerophosphate (2nd
concentration)
Min et al.
(2015)
MBG: 80% SiO2, 15% CaO,
5% P2O5 by percentage
mol
MBG synthesized by using
non-ionic block copolymers
as structure-directing agents
through an EISA process
The dried gel was calcined at
700 ◦C for 5 h to obtain the
final MBG products
DMOG delivering scaffold composed
of MBG and PHBHHx polymers were
fabricated
using a 4th generation 3D-Bioplotter
system
Rat Skull DMOG and MBG
with PHBHHx
polymers (MPHS
scaffolds)
2 critical-sized
bone defects
with a diameter
of 5mm in 12
rats
1. MPHS
2. MPHS/DMOG
Xin et al.
(2017)
MBG: 80% SiO2, 16% CaO,
4% P2O5 by percentage mol
MBG synthesized by a
modified Stöber method.
MBG nanoparticles were
obtained after removing the
templates and organic
components by sintering in
air at 650◦C for 3 h (2◦C per
min)
MBGNs chemically modified with
photo-cross-linkable GelMA were
further incorporated into GelMA to
fabricate GelMA-G-MBGNs
Rat Skull Photo-cross-
linkable GelMA +
GelMA
1 critical-sized
bone defect
with a diameter
of 5mm in 6
rats
1. Negative Control without scaffold
2. GelMA (not relevant for this study)
3. GelMA/MBGNs
4. GelMA-G-MBGNs
(Continued)
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TABLE 1 | Continued
Paper Glass composition Glass fabrication method Scaffold fabrication method Animal Animal bone
defect
Added
components to
scaffold
Number of
defects
Groups
Qi et al.
(2017)
MBG: 80% Si, 15% Ca,
5% P by percentage mol
MBG synthesized by using
non-ionic block copolymers
as structure-directing agents
through EISA process. The
dried gel was calcined at 700
◦C for 5 h to obtain the final
MBG products
MBG-PHBHHx composite
scaffolds were prepared by
freeze-drying and a particulate
leaching technique
Rat Skull DMOG +
rhBMP-2
2 critical-sized
bone defects
with a diameter
of 5mm in 24
rats
1. Pure MBG-PHBHHx = PHMG
2. BMP-2/MBG-PHBHHx = PHMB
3. DMOG/MBG-PHBHHx = PHMD
4. BMP-2/DMOG/MBG-PHBHHx =
PHMBD.
Li et al. (2019) MBG: 80% SiO2, 15% CaO,
5% P2O5
MBG synthesized by using
non-ionic block copolymers
as structure-directing agents
through EISA process for
72 h. The dried gel was then
calcined at 700◦C for 5 h and
thoroughly ground and sieved
to obtain MBG powders
Scaffolds consisting of pure PLGA
matrix or MBG-incorporated PLGA
matrix were fabricated by a
supercritical CO2 foaming technique
Rat Skull Bioactive lipid
FTY720
2 critical-sized
bone defects
with a diameter
of 5mm in 24
rats
1. Negative control
2. PLGA (not relevant for this study)
3. MBG-PLGA
4. FTY/MBG-PLGA
Jia et al.
(2015)
1. Silicate 13–93: 54.6%
SiO2, 6.0% Na2O, 7.95%
K2O, 7.7% MgO, 22.1%
CaO, 1.7% P2O5 by
percentage mol. 2.
Borosilicate 2B6Sr: 18.0%
SiO2, 36.0% B2O3, 6.0%
Na2O, 8.0% K2O, 2.1% MgO,
6.0% SrO, 22.0% CaO, 2.0%
P2O5
by percentage mol
Not specified. The bioactive
glass was sourced from a
commercial source
(SEM-COM Co. Toledo, OH)
Direct ink writing technique was used
with glass inks prepared and a robotic
deposition device used to extrude the
inks through a 250µm nozzle. After
extrusion, the scaffolds were dried in
air and then heated at 1◦C per min to
600◦C to decompose the
organic polymers before sintering at
700◦C for 1 h (13–93 glass) and
620◦C for 2 h (2B6Sr glass)
Rabbit Femur None 1 critical-sized
defect 10mm in
length in 44
rabbits
1. Negative control without scaffold
2. Autologous bone graft (not
relevant for this study)
3. 13–93 glass scaffolds
4. 2B6Sr glass scaffolds
Zhao et al.
(2015)
MBG: 57.2% SiO2, 7.5%
P2O5, 35.3% (SrO + CaO) by
percentage weight
The MBG powders were
calcined from room
temperature to 650◦C with a
heating rate of 1◦C per min in
air, and maintained at 650◦C
for 6 h to remove the organic
structure-directing agents
completely
Sr-MBG scaffolds were fabricated
using a commercial 3D Bioplotter
printing device (EnvisionTEC GmbH,
Germany). Cylinder models were
loaded and scaffolds printed
layer-by-layer through the extrusion of
the paste as a fiber
Rat Skull Sr 2 critical-sized
defects with a
diameter of
5mm in 18 rats
1. Negative control without scaffold
2. MBG
3. Sr-MBG
Summary table detailing author names, publication year, composition of bioactive glass scaffold, glass fabrication method, animals used, bone defects used, added components to the bioactive glass scaffolds, number of bone defects
in each animal, and the experimental groups used in each study.
45S5, glass with 45 wt.% of SiO2 and 5:1 molar ratio of Calcium to Phosphorus; Cu-BG NPs, copper-containing bioactive glass nanoparticles; DMOG, dimethyloxallyl glycine; EISA, Evaporation-Induced Self-Assembly; FTY720,
fingolimod; GelMA-G-MBGNs, MBGNs with photo-cross-linkable GelMA which have been further integrated into GelMA; GelMA, gelatin derivative containing gelatin + methacrylicanhydride; PHBHHx, poly(3-hydroxybutyrate-co-3-
hydroxyhexanoate); MBG, mesoporous bioactive glasses; GO, graphine oxide; MBGN, mesoporous bioactive glass nanoparticle; MPHS, mesoporous bioactive glass with poly(3-hydroxybutyrate-co-3-hydroxyhexanoate); mol, moles;
Mm, millimeters; PLGA, poly (lactic-co-glycolic acid); rhBMP-2, recombinant human bone morphogenetic protein-2; Sr, strontium.
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VEGF (Jia et al., 2019). They could also help stimulate mineral
deposition and osteoblast marker gene expression. Quinlan et al.
found that using cobalt bioactive glass with a particular particle
size could encourage the formation of VEGF and could also
help osteoblast cell proliferation irrespective of particle size in
vitro (Quinlan et al., 2015). These in vitro analyses can provide
an evaluation of cell differentiation and proliferation, as well as
cytotoxicity (Hanks et al., 1996), and avoid the unnecessary use of
animals. However, it is well-documented that in vitro studies can
only conduct evaluations of toxicity in the short term, due to the
short lifespan of cultured cells (Pizzoferrato et al., 1994). Further,
in vitro evaluation test more simplified parts of the more complex
in vivomechanisms due to the fact that in vivo cells often interact
with another (Pizzoferrato et al., 1994). It is therefore important
to evaluate scaffolds in vivo.
It is also important that we have viable methods to assess the
efficacy of these scaffolds in vivo to promote angiogenesis and
osteogenesis. Advances in micro-CT has allowed studies to assess
the mineralization of bone formation spatially and temporally in
a non-destructive way (van Lenthe et al., 2007) and can provide
information such as bone mineral density (BMD), bone volume
fraction and new bone volume. Immunohistochemistry has
allowed studies to investigate angiogenesis. A plethora of growth
factors have been shown to promote angiogenesis. For example,
VEGF has been shown to stimulate endothelial proliferation
and migration (Ferrara et al., 1992). Other endothelial specific
markers include CD31 and CD34 (Miettinen et al., 1994).
Detection of such markers allow for an easy way to identify
blood vessels and endothelial cells (Lu et al., 2006). Another
way in which this can be assessed is the use of Microfil R©
perfusion and subsequent micro-CT. This method enables not
only the visualization of blood vessels but the quantitative
characterization of blood vessels and their branching (Ehling
et al., 2014) and so is considered to be superior to angiography
or blood vessel casting (Lu et al., 2006).
Due to the aforementioned advantages of these methods,
only studies which included an immunohistochemistry or
Microfil approach to assess angiogenesis combined with micro-
CT analyses for osteogenesis were included in this study.
This provides a more robust assessment of scaffolds and their
outcomes of angiogenesis and osteogenesis in these in vivo
studies. As previously mentioned, several studies in the literature
utilize scaffolds which have added biochemical components.
Due to the heterogeneity in the components added, few
systematic reviews have included such studies. We provide a
comprehensive, update on in vivo studies looking at bioactive
glass- containing non-cellular scaffolds with or without added
biochemical components for osteogenesis and angiogenesis.
METHODS
A literature search was performed across three databases,
PubMed, Scopus and EMBASE, in November 2019 using the
search terms “bioactive glass ANDbone AND angiogenesis” from
2015 to present. The inclusion criteria were as follows: (1) in vivo
animal studies, using surgically-created bone defects, without
any pre-treatment, to assess bone regeneration, (2) published
in a peer-reviewed journal, (3) published from 2015 onwards,
(4) containing study groups with no additional cells seeded
in a bioactive glass-containing scaffold, (5) with the scaffold
being implanted directly into the bone defect, (6) assessing
both angiogenesis and osteogenesis to establish extent of bone
regeneration in model, (7) assessing angiogenesis using either
immunohistochemistry or Microfil R© perfusion method, and
(8) assessing osteogenesis using micro-CT method. Exclusion
criteria were: (1) all in vitro studies, (2) conference papers, (3)
studies not published in English, and (4) articles for which the
full-text version was not freely accessible.
Title and abstract screening was performed by four authors
(CKIR, CDSR, JCR, and DS) on the non-duplicate articles
retrieved by the initial search against the inclusion criteria. An
additional hand search was also performed on pertinent review
articles for any articles that might have been missed by the
initial search. Full-text articles were retrieved for those chosen for
further assessment.
RESULTS
The outline of the search results is displayed in Figure 1.
To be included in this review, studies must have used
bioactive glass-containing scaffolds and implanted them directly
into a bone defect. Those that did not directly insert them
into a bone defect are referred to as “ectopic implantation
method.” Those that treated the bone to cause osteonecrosis
before creating the bone defect were also excluded and
are referred to as “uses pre-treatment.” Articles must have
reported outcomes for both angiogenesis, in the form of
either Microfil R© perfusion or immunohistochemistry, and
osteogenesis, in the form of micro-CT. Those that did not
report a measure of angiogenesis are given as “no measure of
angiogenesis.” Articles that did not report using the appropriate
outcome measures detailed above are given as “incorrect
outcome measure.”
The initial search and hand search for this systematic review
returned nine studies. The study characteristics of these nine
papers are detailed in Table 1. Table 2 shows the results of the
studies included in this review.
Demographic Features of Animal Models
In total, 202 animals were surgically treated to form experimental
models with critical-sized bone defects. Of these, 158 subjects
were rats whilst Jia et al. (2015) used rabbit models. In 70
(34.7%) animals across three papers, a single defect (Jia et al.,
2015; Qi et al., 2017; Jing et al., 2018) was surgically created,
whilst the other 132 (65.3%) animals across six papers sustained
two defects (Min et al., 2015; Zhao et al., 2015; Qi et al.,
2017; Li et al., 2019; Wang et al., 2019; Wu et al., 2019).
The length of time for which the scaffold was implanted
before termination of the experiment ranged from 8 weeks
to 3 months with one paper examining their findings at two
end dates (both 4- and 8-weeks post-implantation) (Xin et al.,
2017).
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FIGURE 1 | Systematic review study selection flow chart.
Features of the Scaffolds
All studies included in this review used different bioactive glass
compositions and/or glass fabrication methods to create them,
as shown in Table 1. Eight (Min et al., 2015; Zhao et al., 2015;
Qi et al., 2017; Xin et al., 2017; Li et al., 2019; Wu et al.,
2019) out of the nine papers included added components to
the bioactive glass scaffold. These studies can be divided into
3 broad categories. Firstly, those that incorporated additional
elements into the bioactive glass network (Jia et al., 2015;
Zhao et al., 2015; Wu et al., 2019). Secondly, those that used
additives to the scaffold (Xin et al., 2017; Li et al., 2019; Wang
et al., 2019). Finally, those that used biochemical factors (Min
et al., 2015; Qi et al., 2017). These findings are summarized in
Table 1.
Do the Scaffolds Induce Osteogenesis?
In order to be included in this review, articles must have used
micro-CT to evaluate osteogenesis. These results are detailed in
Table 2. All nine papers showed evidence of bone regeneration
when the bioactive glass was present, which, in the seven
experiments where this was applicable (Jia et al., 2015; Min et al.,
2015; Zhao et al., 2015; Xin et al., 2017; Jing et al., 2018; Li
et al., 2019; Wu et al., 2019) was increased compared to the
non-bioactive glass treated control.
Four papers assessed BMD as an indicator of osteogenesis.
Both Zhao et al. (2015) and Wu et al. (2019) found that there
was significantly increased bone formation seen on micro-CT
in animals treated with bioactive glass scaffolds compared to
negative controls or animals treated with scaffolds which did
not include bioactive glass, respectively. Wang et al. (2019)
and Qi et al. (2017) did not include a negative controls,
with all experiments using bioactive glass. Both papers showed
that BMD was seen to improve across all groups and was
significantly increased in bioactive glass scaffolds treated with
other substances, this has been further discussed below.
Of the nine papers, only six used micro-CT to assess the
bone volume fraction [bone volume/total volume (BV/TV)].
Wang et al. (2019) and Qi et al. (2017) found similar results
as with BMD testing; again, the micro-CT assessment of bone
volume fraction showed significantly increased osteogenesis in
bioactive glass scaffolds treated with other substances. This is
demonstrated in Figures 2E,F. The appearance of the calvarial
bone defects at 8 weeks after implantation is shown in
Figures 2A–D. Both Xin et al. (2017) andWu et al. (2019) showed
that the gels with bioactive glass nanoparticles showed significant
increases in bone volume fraction compared to those treated
without bioactive glass. Zhao et al. (2015) observed significantly
greater bone volume fraction in MBG scaffolds group compared
to the negative control group, with the Strontium- supplemented
MBG scaffold showing significantly greater improvement than all
other scaffolds. Li et al. (2019) found that FTYwith bioactive glass
and PLGA scaffolds showed the greatest increase in bone volume
fraction compared to all other groups including the negative
control. The MBG-PLGA group also showed a significantly
greater increase bone volume fraction than the PLGA alone
group as well as the negative control group. This effect on
osteogenesis is demonstrated in Figures 3E,G. The micro-CT
appearance of calvarial bone defects at 8 weeks is seen in
Figure 3A whilst the blood vessels are seen in Figure 3B. The
osteogenesis at week 8 is displayed by staining in Figure 3C.
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TABLE 2 | Study results.
Paper Evidence of osteogenesis (micro-CT) Evidence of angiogenesis
Immunohistochemistry results Microfil® perfusion results
Jing et al. (2018) 12W: in the group using 45S5 Bioglass scaffold alone,
new bone was created and partially repaired the bone
defect. This was compared to the negative control in
which minimal bone was created
12W: CD31 and VEGF staining: number of
both CD31 and VEGF-positive microvessels
were significantly higher with 45S5 bioactive
glass scaffold treated defects compared to
the negative control experiments (p < 0.05)
Wang et al. (2019) 12W: New bone formation was seen in all groups
however this was markedly increased in groups treated
with bioactive glass scaffolds treated more graphene
oxide:
Bone mineral density: MBG-HGO showed
significantly greater BMD (0.64 ± 0.08 g/cm3) than
MBG group (0.10 ± 0.04 g/cm3 ) and MBG-LGO group
(0.50 ± 0.04 g/cm3 ) (p < 0.05). MBG-LGO showed
significantly greater bone mineral density than the
MBG group (p < 0.05)
Bone volume fraction: MBG-HGO showed
significantly greater bone volume/total volume than
MBG group and MBG-LGO group (p < 0.05).
MBG-LGO showed significantly greater bone
volume/total volume than MBG group (p < 0.05)
4W: CD34 staining: showed very little
staining with pure bioactive glass scaffolds,
however, staining was very strong in
bioactive glass scaffolds treated with
graphene oxide
12W: Microfil® perfusion experiments:
showed that there were higher levels of new
vascularization with graphene oxide treated
bioactive glass scaffolds
Wu et al. (2019) 8W: Bone mineral density and bone volume
fraction: In comparison to gels without bioactive
glass, gels with bioactive glass showed significantly
increased levels of osteogenesis as measured by BMD
and bone volume fraction. Adding copper to the
bioactive glass-silk fibroin-chitosan composite further
increased levels of osteogenesis, showing full repair of
the defect
Cu-BG/CH/SF/GP(II) gel had highest BMD and BV/TV
8W: α smooth muscle (α-SMA) antigen
staining: slight staining present in both
bioactive glass containing group
(BG/CH/SF/GP) and non-bioactive glass
containing group (CH/SF/GP). Copper
treated bioactive glass containing groups
Cu-BG/CH/SF/GP (I) and Cu-BG/CH/SF/GP
(II) gel showed significantly more staining
than those without copper (BG/CH/SF/GP
and CH/SF/GP)
Min et al. (2015) 8W: markedly increased bone growth was observed in
defects treated with bioactive glass scaffolds
(+/–DMOG loading) compared to controls treated
without an implant
8W: Microfil® perfusion experiments:
showed new vascularization in the bone
defects implanted with bioactive glass
scaffolds (+/–DMOG loading). DMOG
loaded bioactive glass scaffolds showed
more ingrowth of dense vessels into the of
the defect compared to DMOG-unloaded
bioactive glass scaffolds, which promoted
growth around the periphery
Xin et al. (2017) 4W and 8W: volume of new bone and volume of
mature bone in bioactive glass containing scaffold
groups (GelMA/MBGNs and GelMA-G-MBGNs) was
significantly more than in non-bioactive glass
containing scaffold groups (GelMA and control groups)
Bone volume fraction: GelMA-G-MBGNs >
GelMA/MBGNs > GelMA.
4W: CD31 staining: GelMA-G-MBGNs
group > GelMA/MBGNs group > GelMA
group > control group when measured at
same time interval after implantation (p <
0.05)
Qi et al. (2017) 8W: PHMBD > PHMB> PHMD > PHMG and PHMD
groups in order of osteogenesis
Bone mineral density: BMD was greatest for the
PHMBD group (0.876 ± 0.021g/cm3), which was
significantly greater than the PHMG, PHMB and PHMD
groups. PHMB group had significantly greater BMD
than both PHMG and PHMD groups
CD31 staining: greater in PHMD and
PHMBD than PHMB and PHMG groups
8W: Microfil® perfusion experiments:
New blood vessel areas: PHMBD (86.09
± 3.989%) > PHMD (36.11 ± 3.687%)
>PHMB (21.648 ± 2.459%) >PHMG
groups (1.265 ± 0.415%) (all p < 0.05)
PHMBD group had the greatest area of
neovascularization of defects forming
microvessels and good connectivity
between vessels. Neovascularization was
observed in PMBD and PHMD groups but
less in PHMB group and the least in PHMG
(Continued)
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TABLE 2 | Continued
Paper Evidence of osteogenesis (micro-CT) Evidence of Angiogenesis
Immunohistochemistry results Microfil® perfusion results
Li et al. (2019) 8W: New bone volume: FTY/MBG-PLGA (9.15 ±
1.2%, p < 0.05) > MBG-PLGA (9.15 ± 1.2%, p <
0.05) > PLGA group (all p < 0.05). No difference
between PLGA and controls
Bone volume fraction: FTY/MBG-PLGA >
MBG-PLGA (p < 0.05)
FTY/MBG-PLGA > PLGA (p < 0.01)
FTY/MBG-PLGA> neg control (p < 0.001)
MBG-PLGA> PLGA (p < 0.05)
MBG-PLGA> neg control (p < 0.01)
CD31 staining:
FTY/MBG-PLGA > MBG-PLGA (p < 0.05)
FTY/MBG-PLGA > PLGA (p < 0.01)
FTY/MBG-PLGA> neg control (p < 0.01)
MBG-PLGA> PLGA (p < 0.05)
MBG-PLGA> neg control (p < 0.05)
8W: Microfil® perfusion experiments:
New blood vessel areas: FTY/MBG-PLGA
(21.07 ± 2.02%) > MBG-PLGA group
(10.25 ± 1.26%) > PLGA (4.10 ± 0.84%)
-all p < 0.05
FTY/MBG-PLGA had greatest area
of neovascularization
Jia et al. (2015) 3M and 9M: new bone formation: Both silicate
13–93 and borosilicate 2B6Sr showed significantly
more new bone formation compared to the negative
control
9M: complete bone healing in both silicate 13–93 and
borosilicate 2B6Sr groups compared to negative
control where a gap in defect was observed
CD31 staining:
3M: 2B6Sr glass scaffold >13–93 glass
scaffold and ABG group (P < 0.05)
9M: no difference between 2B6Sr glass
scaffold, 13–93 glass scaffold and ABG
groups
Increased blood vessels observed from 3M
to 9M in 2B6Sr glass scaffold >13–93 glass
scaffold and ABG group
Zhao et al. (2015) 8W: bone mineral density: Sr-MBG scaffolds group
(503.30 ± 88.93mg cm−3 ) > MBG group (339.30 ±
36.61mg cm−3) > negative control group (58.67 ±
20.65mg cm−3) (all p < 0.05)
Bone volume fraction: Sr-MBG scaffolds group
(31.33 ± 4.93%) > MBG scaffolds group (17.67 ±
5.03%) > negative control group (4.33 ± 1.52%) (all
p < 0.05)
8W: Microfil® perfusion experiments:
New blood vessel areas and vessel
number: Sr-MBG scaffold > MBG scaffold
> negative control (all p < 0.05)
Summary table detailing author names, publication date, evidence of osteogenesis measured using micro-CT and evidence of angiogenesis, measured using Microfil® perfusion and
immunohistochemistry, after implantation of bioactive glass scaffolds into animal models.
45S5, glass with 45 wt.% of SiO2 and 5:1 molar ratio of Calcium to Phosphorus; ABG, autologous bone graft; BMP-2, human bone morphogenetic protein-2; BV/TV, bone
volume/total bone volume; CD31, cluster of differentiation 31; CD34, cluster of differentiation 34; Cu-BG/CH/SF/GP(II), copper-doped bioactive glass with chitosan (CH)/silk fibroin
(SF)/glycerophosphate (GP) concentration 2; Cu-BG/CH/SF/GP, copper-doped bioactive glass with chitosan (CH)/silk fibroin (SF)/glycerophosphate (GP) concentration 1; DMOG,
dimethyloxallyl glycine; FTY720, fingolimod; GelMA-G-MBGNs, mesoporous bioactive glass nanoparticles (MBGNs) with photo-cross-linkable GelMA which have been further integrated
into GelMA; GelMA, gelatin derivative containing gelatin+ methacrylicanhydride; M, months; MBG-LGO, mesoporous bioactive glass- low graphene oxide; MBG- PHBHHx, (MBG)-
doped poly(3-hydroxybutyrate-co-3-hydroxyhexanoate); MBG-HGO, mesoporous bioactive glass- high graphene oxide; MBG, mesoporous bioactive glasses; PHMB, BMP-2 +
MBG-PHBHHx; PHMBD; BMP-2 + DMOG +MBG-PHBHHx; PHMD, DMOG +MBG-PHBHHx; PHMG, pure MBG-PHBHHx; VEGF, vascular endothelial growth factor; W, weeks. The
bold values display the timing when each result was measured, and which method was used to do this.
Figure 3D shows sequential fluorescent labeling to display the
degree of bone mineralisation in each scaffold. Figure 3F shows
quantitatively the degree of osteogenesis using staining and
Figure 3H using fluorescent labeling.
Jia et al. (2015) found that, if left for 9 months, both
the bioactive glass containing scaffolds, namely silicate 13–93
and borosilicate 2B6Sr, induced significantly more new bone
formation compared to the negative control.
Do the Scaffolds Induce Angiogenesis?
The studies included in this review assessed angiogenesis
using two methods: immunohistochemistry to evaluate
new blood vessel formation by staining vascular
endothelium or by visualizing neo-vasculature using
CT with Microfil R© perfusion. These results are detailed
in Table 2.
Of the nine papers included in this review, seven used
immunohistochemistry to investigate the angiogenesis-
promoting qualities of bioactive glass (Jia et al., 2015; Qi
et al., 2017; Xin et al., 2017; Jing et al., 2018; Li et al., 2019; Wang
et al., 2019; Wu et al., 2019). The majority of the papers used
CD31, where three out of five the included papers found that
positively staining micro vessels were significantly increased in
the experiments which included bioactive glass, in at least one
time point (Xin et al., 2017; Jing et al., 2018; Li et al., 2019).
This effect, in the study by Li et al. (2019), is demonstrated in
Figures 4A,B. Notably, Jia et al. (2015) found that although
there was a significant increase in density between the 2B6Sr
containing scaffold compared to the 13-93 and ABG groups at 3
months, this difference was not observed at 9 months. Similarly,
Qi et al. (2017) observed that although neovascularization and
CD31 staining was seen in all bioactive glass treated groups, this
was increased in BMP-2+DMOG+MBG-PHBHHx scaffolds
and PHMD compared to the PHMB and PHMG, thus suggesting
that DMOG helps to increase angiogenesis. Three other stains
were also used, each by a single paper. Similar to their CD31
findings, Jing et al. (2018) observed that the number of VEGF-
positive blood vessels were significantly higher in bioactive glass
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FIGURE 2 | The effect of mesoporous bioactive glass containing groups on osteogenesis. The representative 3D reconstructions of superficial (A1–D1), interior
(A2–D2), and sagittal images (A3–D3) of calvarial bone defects taken at 8 weeks after implantation are shown. Morphometric analysis of (E) BMD and (F) BV/TV is
also shown as determined by micro-CT for each group at 8 weeks (*p < 0.05). MBG, mesoporous bioactive glasses; PHMB, BMP-2 + MBG-PHBHHx; PHMBD,
BMP-2 + DMOG + MBG-PHBHHx; PHMD, DMOG + MBG-PHBHHx; PHMG, pure MBG-PHBHHx. Figure and caption reused from Qi et al. (2017). Used under the
Creative Commons License (https://creativecommons.org/licenses/by/4.0/legalcode).
treated experiments compared to negative controls, suggesting
higher levels of angiogenesis with bioactive glass. In contrast,
Wang et al. (2019) found limited CD34 staining in bone defects
treated with bioactive glass alone, whilst there was more staining
as the concentration of graphene oxide used increased. However,
there was no negative control used in this study for comparison.
Similarly, Wu et al. (2019) found similar smooth muscle (α-
SMA) antigen staining in the bioactive glass containing group
(BG/CH/SF/GP) compared to the non-bioactive glass containing
group (CH/SF/GP).
In summary, the addition of bioactive glass alone increased
angiogenesis marker staining in four of nine papers (Jia et al.,
2015; Xin et al., 2017; Jing et al., 2018; Li et al., 2019), but this
was not significant in the experiments by Wu et al. (2019) and
can’t be assessed with Wang et al. (2019) as they did not test the
effect of bioactive glass alone. Five out of nine papers included
in this review assessed angiogenesis through analyzing Microfil R©
perfusion studies (Min et al., 2015; Zhao et al., 2015; Qi et al.,
2017; Li et al., 2019;Wang et al., 2019). All of these papers showed
evidence of angiogenesis and the formation of new blood vessels
in the bone defect, although this process could be enhanced by
the addition of other substances. Notably, both Li et al. (2019)
and Zhao et al. (2015) showed that scaffolds containing bioactive
glass induced significantly greater new blood vessel area than
those without.
Studies Reporting Relative Increase in
Angiogenesis and Osteogenesis
Five out of nine studies (Min et al., 2015; Zhao et al., 2015; Xin
et al., 2017; Jing et al., 2018; Li et al., 2019) showed increases in
both angiogenesis and osteogenesis in bioactive glass-containing
scaffolds compared to scaffolds without bioactive glass (Xin et al.,
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FIGURE 3 | Osteogenesis and aniogenesis in critical sized calvarial bone defects. (A) Micro-CT images for the bone repair in calvarial defects of different groups after
8 weeks of implantation. (B) Micro-CT observation of the newly-formed blood vessels perfused with Microfil in the defect regions (as indicated by the white circle) at
week 8. (C) New bone formation observed by Van Gieson’s picrofuchsin staining at week 8 (red, new bone; blue, residual material). (D) Sequential fluorescent labeling
observation for dynamic bone mineralization, Alizarin Red S (AL, week 4), and Calcein (CA, week 6). Quantitative data (n = 3) from micro-CT analysis of BV/TV, bone
volume fractions (E) and blood vessel volume in the defect area (F). The quantitative analysis of the new bone area of Van Gieson’s picrofuchsin staining (G) and
sequential fluorescent labeling (H). *P < 0.05, **P < 0.01, ***P < 0.001 compared with control group; #P < 0.05, ##P < 0.01 compared with PLGA group; +P <
0.05 compared with MBG-PLGA group. PLGA, poly(lactic-co-glycolic acid); MBG-PLGA, mesoporous bioactive glass and poly(lactic-co-glycolic acid) scaffold;
FTY/MBG-PLGA, FTY720 with mesoporous bioactive glass and=poly(lactic-co-glycolic acid) scaffold. Figure and caption reused from Li et al. (2019). Used under the
Creative Commons License (https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode).
2017; Li et al., 2019) or negative control groups (Min et al., 2015;
Zhao et al., 2015; Jing et al., 2018).
Wu et al. (2019) showed that, although the bioactive glass
containing scaffolds showed increased levels of osteogenesis
compared to those without bioactive glass, they did not always
show an increase in angiogenesis compared to those without. Jia
et al. (2015) showed that although both bioactive glass containing
scaffolds showed completemore osteogenesis than in the negative
control, there was no comment on the extent of angiogenesis
in the negative control for comparison. As all groups contained
bioactive glass, the results of Qi et al. (2017) and Wang et al.
(2019) cannot be commented on in this respect.
Effects of Changing the Composition of the
Bioactive Glass Scaffolds
Seven out of the nine papers included in this review studied
bioactive glass scaffolds with added non-cellular components as
outlined below. These can be broadly divided into components
which were incorporated into the bioactive glass network,
additives, and finally biochemical factors.
Incorporation of Additional Elements Into Bioactive
Glass Network
Ions and inorganic compounds: Three papers investigated the
effect of incorporating metals into the bioactive glass network.
Jia et al. (2015) added boron trioxide (borosilicate) to the
bioactive which made for very successful scaffolds. Increased
osteogenesis compared to the negative control was observed for
both silicate and borosilicate scaffolds, whilst for angiogenesis,
the borosilicate-containing bioactive glass scaffold showed higher
levels of CD31 positively stained vasculature initially, but by
9 months there was no difference between the two scaffolds.
Zhao et al. (2015) also found that although the addition
of mesoporous glass showed more favorable outcomes with
both osteogenesis and angiogenesis, however, the addition of
strontium improved outcomes in terms of bone growth, bone
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FIGURE 4 | Angiogenesis in critical sized calvarial bone defects, using CD31hi and Emcnhi immunofluorescence staining for calvarial defect sections. (A)
Immunofluorescence staining images of CD31 and Emcn for the calvarial defect sections from various groups (green, CD31; red, Emcn; blue, cell nuclei). (B) The
quantitative analysis of CD31hiEmcnhi cells per mm2 from the staining results, n = 5. *P < 0.05, **P < 0.01 compared with control group; #P < 0.05, ##P < 0.01
compared with PLGA group; +P < 0.05 compared with MBG-PLGA group. PLGA, poly(lactic-co-glycolic acid); MBG-PLGA, mesoporous bioactive glass and
poly(lactic-co-glycolic acid) scaffold; FTY/MBG-PLGA, FTY720 with mesoporous bioactive glass and=poly(lactic-co-glycolic acid) scaffold. Figure and Caption reused
from Li et al. (2019). Used under the Creative Commons License (https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode).
volume fraction and angiogenesis. Similarly, Wu et al. (2019)
found that the addition of copper allowed for a full repair of
the bone defect, whilst bioactive glass alone only allowed for
partial repair. Furthermore, α smooth muscle (α-SMA) antigen
staining was greater in copper treated scaffolds. Micro-CT
results further corroborated these results with copper improving
osteogenesis as observed on micro-CT, significantly higher BMD
and BV/TC.
Use of Additives to the Bioactive Glass Scaffold
Wang et al. (2019) examined the effects of adding graphene oxide
to bioactive glass scaffolds. Micro-CT showed markedly
increased osteogenesis in groups treated with higher
concentrations of graphene oxide in the bioactive glass.
Moreover, angiogenesis was also seen to be increased as
shown by CD34 staining and Microfil R© perfusion experiments
in bioactive glass containing graphene oxide compared to
those without.
Two papers evaluated the effect of bioactive glass when
used in combination with organic polymers to form a scaffold.
Xin et al. (2017) found that crossing linking MBGNs with
photo-cross-linkable GelMA and then incorporating GelMA
increased angiogenesis, as shown by significantly higher levels
of CD31 staining at 4 weeks compared to scaffolds just
created by chemically modifying mesoporous bioactive glass
nanoparticles with photo-cross-linkable GelMA. Furthermore, Li
et al. (2019) found that MBG-PLGA composite scaffolds were
more effective at inducing osteogenesis when the bioactive lipid,
FTY720, was added, as shown by micro-CT study. Microfil R©
perfusion studies and CD31 staining showed a similar effect
on angiogenesis.
Use of Biochemical Factors
Two out of the nine papers included in this paper assessed the
effect of the addition of osteoinductive biochemical factors. One
of the factors was DMOG. Qi et al. (2017) found that BMD
was highest in the bioactive glass group treated with DMOG as
well as BMP-2 along with angiogenesis as observed with CD31
staining. In experiments by Min et al. (2015) angiogenesis was
observed with bioactive glass with or without the addition of
DMOG. However, DMOG loaded scaffolds showed an advantage
as they promoted the ingrowth of dense vessels into the center of
the defect, whilst unloaded bioactive glass scaffolds encouraged
growth around the periphery.
DISCUSSION
The regenerative capacity of bioactive glass scaffolds are
dependent on a number of factors including the composition
of the bioactive glass scaffolds, the method of fabrication
and the microstructure of the scaffold amongst others (El-
Rashidy et al., 2017). Although bioactive glass could enhance
bone formation, more research is needed to characterize the
influencing factors. This review attempts to elucidate the
effects of non-cellular bioactive glass-containing scaffolds on
osteogenesis and angiogenesis in bone defect by analyzing the
in vivo animal literature.
Osteogenesis and Bioactive Glass
Scaffolds
Osteogenesis was initially thought to take place through the
dissolution of particles (in the original 45S5 Bioglass R© causing
an HCA layer to form rapidly, the glass degrading and then
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allowing space for bone ingrowth Hench and Jones, 2015. It was
later shown that the dissolution of the bioactive glass particles
releases ions that acted as signals into the cells, prompting
upregulation of certain genes and subsequent increases in nuclear
transcription factors, cell cycle regulators, and growth factors
such as insulin-like growth factor II (IGF-II) (Xynos et al., 2000,
2001). Transcription of extracellular matrix (ECM) components
and secretion into a mineralized matrix is thought to lead to the
formation and growth of bone nodules along with differentiation
of the osteocyte phenotype (Hench and Jones, 2015). Individual
ions also play a role, with ions such as calcium being important
for upregulation of osteogenic genes (Hench, 2009) and silicon
important for the formation and calcification of bone tissue
(Carlisle, 1981).
Bone Volume Fraction as an Indicator for
Osteogenesis
Two studies (Qi et al., 2017; Wang et al., 2019) found that
bone volume fraction significantly increased in bioactive glass
scaffolds treated with other substances. Xin et al. (2017) and Wu
et al. (2019) showed that gels with bioactive glass nanoparticles
also had significant increases in bone volume fraction compared
to defects treated without bioactive glass. Similarly, Li et al.
(2019) showed that the bioactive glass containing groups showed
greater increases in the bone volume fraction than those without
bioactive glass. Zhao et al. (2015) found a greater bone volume
fraction in MBG scaffolds than negative controls. Jia et al. (2015)
found that bioactive glass containing scaffolds induced more
bone formation than negative controls.
BMD as an Indicator for Osteogenesis
Wang et al. (2019) and Qi et al. (2017) found that bioactive glass
scaffolds increased BMD. Zhao et al. (2015) and Wu et al. (2019)
found that BMD also increased in animals with bioactive glass
scaffolds compared to negative controls or animals with scaffolds
without bioactive glass. Thus, these results on the whole do
indicate that bioactive glass scaffolds could induce osteogenesis,
with no papers showing an insignificant difference between
control and bioactive glass containing groups.
Angiogenesis and Bioactive Glass
Scaffolds
Angiogenesis is the growth of blood vessels from existing
vasculature, occurring throughout life and can be physiological
or pathological. The two types of angiogenesis are sprouting and
intussusceptive. Intussusceptive angiogenesis is when a vessel
is split into two and is more relevant in embryogenesis than
in the growth of vascular networks into scaffolds. Sprouting
angiogenesis is initiated in hypoxic conditions due to the
expression of VEGF-A by parenchymal cells and a tip cell
guided by filopodia will follow the VEGF gradient using VEGF
receptors. Vacuoles will form and tip cells will fuse forming a
continuous lumen for blood to flow through and once oxygen
is supplied, VEGF-A levels return to normal. Other signaling
pathways such as the delta-notch pathway are also responsible
for sprout formation, but even this pathway is reliant on
VEGF expression demonstrating the importance of the factor
(Adair and Montani, 2010). Markers such as CD31 which is an
endothelial cell-cell adhesion molecule have been shown to be an
indication of new vessel formation (DeLisser et al., 1997), as well
as CD34 which is expressed on tip cells (Siemerink et al., 2012)
and a-SMAwhich is an indication of microvessel density (Tonino
and Abreu, 2011).
One of the indications for the development of bioactive
glass scaffolds, was the potential for enhanced angiogenesis. The
creation of a vascular network is vital for tissue to successfully
regenerate and has been acknowledged as a significant issue in
tissue engineering, particularly for larger tissues such as bone.
Spontaneous growth of vessels has a slow rate and vascularization
of an implant may take weeks, during which time tissue is
unevenly supplied and may centrally go hypoxic (Rouwkema
et al., 2008). Bioactive glass has been shown to be proangiogenic
in vitro, stimulating the expression of VEGF from fibroblasts and
proliferation of microvascular endothelial cells (Day, 2005). The
ionic dissolution products such as Si, which were shown to affect
gene expression in human osteoblasts explaining osteogenic
effects (Xynos et al., 2001), have also been shown to be pro-
angiogenic (Zhai et al., 2012). Calcium silicate has been shown
to stimulate VEGF and VE-cad expression, with silicon ions
determined to have a significant role in angiogenesis by dilution
experiments and calcium ions supplementing the silicon’s effect
(Li and Chang, 2013).
The results from papers on the effects on bioactive glass on
angiogenesis in vivo are mixed. Four papers showed evidence of
bioactive glass alone increasing immunohistochemistry staining
indicating angiogenesis e.g., CD31 (Qi et al., 2017; Xin et al.,
2017; Jing et al., 2018; Li et al., 2019), VEGF (Jing et al., 2018).
Increased Microfil R© perfusion was seen by the only four groups
who tested Microfil R© perfusion for controls or bioactive glass
alone as part of their study (Min et al., 2015; Zhao et al., 2015;
Qi et al., 2017; Li et al., 2019). Wang et al. (2019) did not
compare to control but showed limited staining of CD34 with
bioactive glass alone, whilst Wu et al. (2019) saw no difference in
a-SMA staining between non-bioactive glass and bioactive glass
treated groups. Jia et al. (2015) found no significant difference
in CD31 staining between bioactive glass scaffolds (13–93 silicate
alone) and autologous bone graft controls at 3M and 9M. This is
significant as the three other studies that used CD31 as a marker
and compared angiogenesis to a non-bioactive glass control all
found an increase (Xin et al., 2017; Jing et al., 2018; Li et al., 2019),
but Jia et al. (2015) was also the only paper that used a rabbit
femoral defect instead of rat skull. Although the papers tend to
indicate that bioactive glass has pro-angiogenetic properties, the
results are not as overwhelming as the osteogenic effects and
indicate a potential avenue for future improvement, which will
be discussed below.
How Does Changing the Composition of
Bioactive Glass Scaffolds Impact Their
Properties?
Only a single study reviewed focused on the use of bioactive glass
without any non-cellular additives (Jing et al., 2018). Innovative
scaffolds tend to involve the incorporation of metals, biochemical
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factors and organic compounds. It is important to acknowledge
this variance in composition as the heterogeneity of the scaffolds
makes it difficult to directly compare results.
Incorporating Additional Elements (Boron, Strontium,
Copper) Into the Bioactive Glass Network
Boron seems to have a physiological role in bone where
it accumulates, with recent mechanisms proposed such as
simultaneous activation of the NaBC1 ion channel and VEGFR
(Moseman, 1994). There is also evidence in other models that
boron in bioactive glass allows for enhanced bone formation,
potentially due to its impact on angiogenesis (Gorustovich et al.,
2006). Jia et al. (2015) found boron improved angiogenesis
(assessed by CD31 staining) at 3 months compared to standard
silicate bioactive glass, but this difference was not found at 9
months. This suggests that boron can increase angiogenesis early
but there is no overall effect by the end of 9 months. Zhao
et al. (2015) found strontium both increased BMD and bone
volume fraction on micro-CT as well as Microfil R© perfusion,
therefore having osteogenic and angiogenic benefits. This follows
on from evidence that strontium stimulates bone formation and
reduces bone resorption (Kyllönen et al., 2015). This could be
due to strontium ions’ ability to inhibit receptor activator of
nuclear factor kappa-B ligand (RANKL) in mesenchymal stem
cells, thereby inhibiting osteoclast differentiation (Marie et al.,
2011). Strontium also promotes vessel formation by stimulation
of VEGF, MMP-2 etc. (Zarins et al., 2017). Copper also increased
osteogenic and angiogenic effects of bioactive glass, particularly
angiogenesis (a-SMA) which was similar between controls and
standard bioactive glass (Wu et al., 2019). A link between copper
and bone health has been established previously (Qu et al.,
2018) and has been found to have osteostimulation properties,
facilitating new bone formation (Wu et al., 2013b). The ion also
stimulates angiogenic factor expression such as VEGF and HIF-1
(Du et al., 2018). Copper and silicon ions have also been reported
to have synergistic effects on angiogenesis in vitro (Kong et al.,
2014).
Using Additives (Graphene Oxide and Organic
Polymers) in Bioactive Glass Scaffolds
Wang et al. (2019) used graphene oxide, an inorganic compound,
and found that not only did the addition increase osteogenesis
and angiogenesis (assessed by both CD34 and Microfil R©
perfusion), but a high amount had significantly better results than
a low amount of graphene in the scaffold. This was particularly
evident in the CD34 staining, which was limited in the use of
standard bioactive glass scaffolds. Graphene oxide is a conductive
material, which are known to enhance bone repair, and it is
known to induce osteoblastic differentiation and mineralization
(Cheng et al., 2018).
MBG-PLGA (PLGA alone was equivalent to control)
composites were evaluated by Li et al. both with and
without FTY720, a bioactive lipid. FTY720 is used as an
immunosuppressive drug for multiple sclerosis due to a
reduction in peripheral lymphocytes and T cell inhibition (Baer
et al., 2018) with a developing role in cancer therapy (White
et al., 2016). There is evidence local delivery of FTY720 in
calvarial defects increases bone volume (Huang et al., 2012),
potentially by stimulating sphingosine 1-phosphate receptors and
as a result, the local microvascular network (Aronin et al., 2010).
Those with FTY had increased bone volume, CD31 staining and
Microfil R© blood vessel area implying a benefit of this organic
compound. Xin et al. (2017) incorporated photo-cross-linked
GelMA into a bioactive glass nanoparticles scaffold in which
GelMA was part of the composition of the particles. GelMA has
good biocompatibility and is similar to the ECM, as a semi-
synthetic hydrogel. There was no control without any GelMA
at all, but the addition of photo-cross-linked GelMA to the
composite nanoparticles did increase the bone volume fraction
and CD31 staining. It is important at this point to acknowledge
the use of nanoparticles in bioactive glass. Their high surface
to volume ratio and ability to incorporate into matrices more
evenly helps maximize the yield of the bioactive glass in bone
regeneration (Tabia et al., 2019).
The Use of Biochemical Factors (DMOG) in Bioactive
Glass Scaffolds
DMOG is an osteoinductive biochemical factor. It is a
competitive inhibitor of prolyl hydroxylase enzymes which
subsequently leads to less degradation of the angiogenic factor
HIF-1a (Zhang et al., 2016). The osteogenic effects of DMOG are
not clear as Qi et al. (2017) found BMD was better than bioactive
glass alone but for Min et al. (2015) there was no difference.
Nevertheless, both papers found a benefit in angiogenesis. Qi
et al. (2017) saw CD31 staining and Microfil R© perfusion was
greatest with both DMOG and bioactive glass, but interestingly
DMOG alone had a significantly better effect than bioactive
glass alone, which is the opposite to osteogenic results. Min
et al. (2015) also found that DMOG-loaded bioactive glass
scaffolds showed more vessel ingrowth into the center of the
defect compared to bioactive glass alone as opposed to around
the peripheries.
Other Bioactive Glass Scaffolds and the
Future
For this systematic review, any scaffolds with cells added were
excluded due to the potentially drastic impact on bone formation.
Nevertheless, scaffolds now frequently incorporate stem cells
to enhance the potential for regeneration. Adipose-derived
mesenchymal stem cells are commonly the cells used (Handel
et al., 2013; Du et al., 2018) due to the relative ease in obtaining
them and potential for differentiation into multiple relevant cell
types (Strem et al., 2005). Other stem cell types used include
those derived from bone and umbilical cords, with benefits
in particular seen with bone-marrow derived stem cells for
osteogenesis and umbilical cord for angiogenesis on comparison
(Kargozar et al., 2018b). UC-derived stem cells may therefore
be useful in stimulating angiogenesis when added onto bioactive
glass, which as seen from above has a bigger need to be targeted
than osteogenesis.
The future of bioactive glass in bone regeneration is vast.
The biocompatibility and osteogenic effects make it ideal to
encourage the healing of bone defects, as seen both in vitro and
reviewed here in vivo. One avenue that is being explored in
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bioactive glass currently is the controlled release of biomolecules
from the scaffold. This could be utilized in bone regeneration
with targeted drug delivery. The factors released could include
transforming growth factors, bone morphogenetic proteins,
stromal cell-derived factors etc. to imitate in vivo signaling for
repair, many of which are approved for use in humans and
incorporated into implants already (Gothard et al., 2014; Baino
et al., 2018). The other key advancement in bioactive glass
scaffolds, is the structure of these scaffolds. Mesoporous bioactive
glass scaffolds were initially brittle meaning they could not be
used in practice. Developments in 3D printing and polymer
addition have strengthened the scaffold (Baino et al., 2018), but
structure could still be improved, with recent advancements in
nanoparticles increasing the surface area exposed to tissue. A
randomized controlled clinical trial in humans using bioglass
for bone healing after tooth extraction showed preservation of
alveolar bone and enhanced bone remodeling (El Shazley et al.,
2016). Despite this being a very different situation to critical size
bone defects, the successful use of the biomaterial in humans
implies promise for bioactive glass in therapeutics.
Limitations
It is important to highlight the limitations of this systematic
review. First, only three databases were searched (Pubmed,
Scopus, and EMBASE). Additionally, only studies that were in
English were looked at, therefore there might have been some
relevant studies that may have been overlooked. Nine studies
were included in this review, which represents a very small
number in the bioactive glass scaffold literature. The studies
that were included used a variable type of scaffold and used
different animal models limiting any direct comparison between
studies. There was also variability in the methodology of the
studies, for example some studies using BMD as opposed to
bone volume fraction as a marker for osteogenesis, and different
immunohistochemistry markers for angiogenesis. Future studies
using standardized methods of measuring these properties would
help in comparison and making conclusions. Further, some
studies did not include a control, making any definitive causal
conclusions hard to ascertain, as well as only one study evaluating
results at a longer time point of 9 months (Jia et al., 2015). Future
studies should aim to take measurements at more than one time
point and indeed in the long term, which could be important for
clinical translation of such scaffolds from animal defect models
to humans.
CONCLUSION
The data from this systematic review suggests that despite
the heterogeneity of the scaffolds and markers assessed,
there is consistent evidence that bioactive glass does improve
bone regeneration in these models, both by osteogenic and
angiogenic measures. This review also highlighted the benefits
of changing the composition of the bioactive glass scaffolds
using 3 methods. Firstly, incorporation of additional elements
into the bioactive glass network such as boron, copper and
strontium. Secondly, the use of additives and finally the use
of biochemical factors. However, comparisons between the
scaffolds are limited by the heterogeneity of study methods.
The future of bioactive glass will broaden as advancements
in technology are made and the structure, composition and
additives for bone scaffolds must be optimized for and
trialed in humans, which will take a significant amount
of research and time. Increased consistency in composition
of scaffold and outcome measures will help in determining
the scaffold with optimal results. Nevertheless, the in vivo
results do confirm that bioactive glass has a future in
bone regeneration.
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